Abstract:e16115 Background: Patients with advanced stage hepatocellular carcinoma (HCC) have a dismal prognosis. The Barcelona Clinic Liver Cancer (BCLC) staging system does not recommend transarterial chemoembolization (TACE) for treating BCLC C HCC. However, numerous Asian-Pacific institutes still perform TACE for this patient group. There remains a paucity of large real-world data characterizing treatment outcomes of these patients.We aimed to share experiences of 885 cases of BCLC C stage HCC patients treated by TACE in real-world practice. Methods: 885 patients were included in this real-world study who received TACE based monotherapy or combination therapy in liver cancer institute, Fudan University between January 2008 and December 2015. We investigated the clinical outcomes of TACE-based treatment in BCLC C stage HCC. Results: In this cohort of 885 BCLC C HCC patients, vascular invasion was present in 582 patients (65.8%), lymph node involvement was present in 108 patients(12.2%), extrahepatic metastases was present in 232 patients (26.2%).The mean number of TACE per patient was 3.0±1.9 sessions. Median overall survival was 8.0 months (range 3-37) for the entire study population. Of all the patients, 600 patients received TACE-alone treatment, 137 patients received TACE combined Sorafenib treatment, 41 patients received TACE combined local regional treatment, 59 patients received TACE with chemotherapy, 123 patients received TACE with radiotherapy. The median survival time was 6.0 months for TACE-alone group, 11.5 months for TACE+Sorafenib group, 19.8 months for TACE+local regional treatment group, 12.0 month for TACE+chemotherapy group and 12.0 months for TACE+radiotherapy group respectively.These data showed that TACE-based combination therapy can improve overall survival in BCLC C stage HCC, in comparison with TACE alone treatment.After propensity score matching and adjusting for potential confounders, there were still significant survival differences between TACE-alone group and TACE-based combination treatments mentioned above. Conclusions: TACE-based combination therapy can improve overall survival in BCLC C stage HCC patients.

Randomized Clinical Trial of Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Intermediate Stage (BCLC Stage B) Hepatocellular Carcinoma Beyond Milan Criteria.

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Surgical Resection Plus Radiofrequency Ablation for the Treatment of Multifocal Hepatocellular Carcinoma.

Hepatic Resection Versus TILA-TACE in the Treatment of Resectable Hepatocellular Carcinoma: Study Protocol for a Randomized Controlled Trial

Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: A randomized clinical trial

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Delays Tumor Progression and Prolongs Overall Survival in Patients with Intermediate (BCLC B) Hepatocellular Carcinoma.

Radiofrequency Ablation Following First-Line Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria

Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma

External-beam Radiotherapy after Transarterial Chemoembolization (TACE) Versus TACE Alone for Treatment of Inoperable HCC: A Randomized Phase III Trial

Comparison of the Efficacy of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation Versus Monotherapy in Patients with Liver Cancer

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial

Comparison of Transarterial Chemoembolization with Radiofrequency Ablation for Unresectable Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma: a Propensity Score Matching.

Elimination Rate Of Tumor'S Blood Supply, Tumor Necrosis Rate And Adverse Reactions In Advanced Hepatocellular Carcinoma Treated By Transcatheter Arterial Chemoembolization With Radiofrequency Ablation

TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study

Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study

Long-term Outcomes of Combined Transarterial Chemoembolization and Radiofrequency Ablation Versus RFA Monotherapy for Single Hepatocellular Carcinoma ≤3 Cm: Emphasis on Local Tumor Progression

Transarterial Chemoembolization Treatment in the Management of BCLC C Stage Hepatocellular Carcinoma: A Large Real-World Observational Study of 885 Cases

Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis

Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study

Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Study

Surgical Resection plus Intraoperative Radiofrequency Ablation versus Chemoembolization for the Treatment of Intermediate-Stage (BCLC B) Hepatocellular Carcinoma with Preserved Liver Function: A Propensity Score-Matched Analysis